Anúncio
Anúncio
TSHA
Taysha Gene Therapies, Inc. Common Stock
4.97
USDPatrocinado
-0.17
-3.37%
09 de jan., 15:59 UTC -5
Encerrado
Pós-Mercado
4.94
-0.03
-0.54%
Relatórios de Lucros TSHA
Rácio de surpresa positiva
TSHA separação 10 de 21 últimas estimativas.
48%
Próximo Relatório
Data do Próximo Relatório
24 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$2.10M
/-$0.09
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/--
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+3.95%
/+28.57%
Taysha Gene Therapies, Inc. Common Stock earnings per share and revenue
On 04 de nov. de 2025, TSHA reported earnings of -0.09 USD per share (EPS) for Q3 25, Inline the estimate of -0.09 USD, resulting in a 0.00% surprise. Revenue reached --, compared to an expected 1.41 milhão, with a -100.00% difference. The market reacted with a -4.26% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analistas forecast an EPS of -0.09 USD, with revenue projected to reach 2.10 milhão USD, implying an aumentar of 0.00% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Taysha Gene Therapies, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Taysha Gene Therapies, Inc. Common Stock reported EPS of -$0.09, missing estimates by 0%, and revenue of $0.00, -100% below expectations.
How did the market react to Taysha Gene Therapies, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.26%, changed from $4.46 before the earnings release to $4.27 the day after.
When is Taysha Gene Therapies, Inc. Common Stock expected to report next?
The next earning report is scheduled for 24 de fev. de 2026.
What are the forecasts for Taysha Gene Therapies, Inc. Common Stock's next earnings report?
Based on 15
analistas, Taysha Gene Therapies, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $2.10M for Q4 2025.
Which companies are reporting earnings today?
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio